Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pharmacyclics, Inc.    PCYC

News SummaryMost relevantAll newsSector newsTweets 

Pharmacyclics Inks Agreement With Novo Nordisk for Molecule Inhibitor

share with twitter share with LinkedIn share with facebook
share via e-mail
10/10/2012 | 12:25am CET
   By Kristin Jones 

Pharmacyclics Inc. (>> Pharmacyclics, Inc.) has inked an agreement with Novo Nordisk A/S (NVO, NOVO-B.KO) giving the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor, according to a regulatory filing.

Pharmacyclics shares rose 3.75% to $67.20 in after-hours trading. Through the close, the stock had more than doubled in the past six months.

Under the terms of the agreement, Novo Nordisk will acquire the world-wide rights to PCI-27483 for specific noncancer-related uses. The Danish company plans to use it as an excipient in an unnamed product within its biopharmaceutical unit.

An excipient is generally an inactive ingredient used to carry or to add a certain consistency to a drug.

Pharmacyclics has been developing PCI-27483 to inhibit the intracellular signaling involved in tumor growth and to thwart the blood clots that afflict some cancer patients.

The biopharmaceutical company expects to receive an upfront payment of $5 million, as well as up to $55 million based on the achievement of certain development, regulatory and sales milestones. It also will receive royalties on sales of Novo Nordisk products that use PCI-27483.

Novo Nordisk's American depositary shares closed Tuesday at $161.38 and were unchanged after hours. The ADS are up 40% so far this year.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pharmacyclics, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PHARMACYCLICS, INC.
2016 PHARMACYCLICS : AbbVie Announces Submission of a Supplemental New Drug Applicati..
2016 PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients..
2016 PHARMACYCLICS : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceuti..
2016 PHARMACYCLICS : AbbVie’s Commitment to Oncology Demonstrated at the 57th A..
2016 PHARMACYCLICS : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s..
2016 PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naï..
2016 PHARMACYCLICS : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naï..
2015 Alexion to bolster rare disease offering with $8.4 billion deal
2015DJAbbVie Wraps Up Large Debt Sale for Pharmacyclics Deal
2015DJAbbVie Wraps Up Large Debt Sale For Pharmacyclics Deal
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 Who's Next After Medivation?
2016 Pfizer Pays Up
2016 Smart-Money Healthcare Investing Focuses On Major Biotech Stocks
2015 Investing In Johnson & Johnson's Pharmaceutical Collaborations Can Provide Dr..
2015 AbbVie - After 10% Drop, Is This The Right Time To Buy?
Robert W. Duggan Chairman & Chief Executive Officer
Mahkam Zanganeh Chief Operating Officer
Manmeet Singh Soni Chief Financial Officer
James N. Lowder Vice President-Clinical Development
Heow Tan Chief Quality & Technical Operations Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 650
LONZA GROUP AG5.05%9 643
ALKERMES PLC-0.22%8 428
More Results